Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 142Myelodysplastic Syndromes 66Leukemia, Myelomonocytic, Chronic 33Neoplasms 17Leukemia 16Recurrence 14Hematologic Neoplasms 14Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Primary Myelofibrosis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Neoplasm Metastasis 4Leukemia, Myeloid 4Hodgkin Disease 4Hematologic Diseases 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Glioblastoma 3Breast Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Renal Insufficiency 2

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × Azacitidine × Clear all
NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Incyte Corporation

Phase 1/2 Terminated
70 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Celgene

Phase 2 Completed
36 enrolled 24 charts
Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡